BD (Becton, Dickinson and Company) has announced plans to invest more than $35 million in expanding its U.S.-based manufacturing of prefilled flush syringes, as part of its broader strategy to enhance the resilience of the domestic healthcare supply chain.
The investment will support increased production at BD’s Columbus, Nebraska facility, creating approximately 50 new jobs and further strengthening the company’s syringe manufacturing capabilities in the U.S.
This move follows earlier expansions in 2024, when BD increased syringe manufacturing capacity in response to FDA warnings regarding syringes produced in China. The company had then installed additional production lines in Connecticut and Nebraska to ensure a stable, high-quality supply for U.S. healthcare providers.
The latest funding will be directed toward boosting production of BD PosiFlush™ prefilled syringes, supporting both product innovation and operational efficiency. These flush syringes are critical in catheter care and maintenance, helping prevent complications such as catheter occlusions and infections. Manufactured through a fully automated, hands-free process, PosiFlush syringes are designed so that the first person to handle the syringe is the clinician, reducing the risk of contamination.
“BD PosiFlush syringes are essential to everyday patient care for keeping catheters clear and safely delivering medications,” said Eric Borin, Worldwide President of BD Medication Delivery Solutions. “Our latest investments boost U.S. production capacity and reinforce our commitment to a reliable supply for healthcare providers and the patients they serve.”
This announcement is part of BD’s larger $2.5 billion investment plan to expand its U.S. manufacturing footprint over the next five years. In total, BD has invested more than $80 million in expanding PosiFlush production capacity over the past three years to meet rising demand from hospitals and health systems.